Australian Progen CEO Says Oncology Pipeline Advances Despite Troubles
This article was originally published in PharmAsia News
Australia's Progen Pharmaceuticals says it is staying on track and pushing its anti-cancer drugs through its pipeline despite several upheavals that have plagued it for the past six months. CEO Justus Homburg presented an upbeat view of the company's prospects, such as its metastatic melanoma drug now about to enter Phase II trials. Progen also says its small-molecule heparanese inhibitor discovery program also is getting encouraging results. Progen has been under attack by two separate groups of shareholders, including another cancer drug developer with stock, Cytopia, which also helped derail a Progen merger with Avexa. (Click here for more
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.